To believe or not to believe in the dietary guideline to reduce intake of saturated fat? This is the emotive question that has fuelled contentious debate between health professionals, journalists and the general public, for which a more definitive answer is now beginning to emerge. The conclusions of two independent draft reports from the Scientific Advisory Committee on Nutrition's (SACN 2018) 'Saturated fat working group', and the World Health Organization (WHO 2018), albeit still under consultation, provide clear and solid affirmation for the validity of our existing dietary guidelines on saturated fat. The coincidental joint publication of these reports, within 24 hours, was also fortuitous in reinforcing this recommendation in the UK and globally, and will serve to stimulate further research into the outstanding knowledge gaps identified within the reports. The purpose of this editorial is to provide a brief overview of these two reports, and update the current status quo on the saturated fat saga in light of this new evidence. An aim is to provide some insight into the key events in the long-and much shorter term history of saturated fatty acids (SFA) and cardiovascular disease (CVD), in an attempt to understand how polarised views on a dietary guideline can develop and take hold of public opinion. We will also address this dietary guideline within the context of the role of unsaturated fatty acids, carbohydrates, whole foods and dietary patterns, and dispel some popular misconceptions along the way. In closing, we will address the wider implications for the impact of this dietary guideline in affecting cardio-metabolic health and reducing CVD risk associated with obesity and type 2 diabetes.
There is a fundamental point to stress at the outset, which appears to have escaped the attention of most secondary meta-analyses, the purpose of which was to find evidence for a direct relationship between dietary SFA and CVD mortality. This point is, that the strength of the relationship between SFA and the development and clinical endpoints of CVD, and underlying foundation of the dietary guideline, rests largely on the capacity of SFA to raise serum low density lipoprotein (LDL) cholesterol. SFA and CVD are not linked directly by a straight line but by a triangle, two sides of which are supported by irrefutable evidence that LDL is a causal risk factor for the development of atherosclerosis (The 'Cholesterol or lipid hypothesis', reviewed by Griffin 2017) and that certain SFA raise serum LDL-cholesterol (Fig. 1) . The evidence for the third side of this triangle, that SFA are causally related to CVD and coronary heart disease (CHD) mortality (The 'Diet-heart hypothesis') is, however, relatively much weaker, though there is now compelling evidence to suggest that replacing SFA with unsaturated fatty acids reduces both the relative risk of developing CVD (morbidity), and cardiac events (e.g. myocardial infarction; MI).
Origins and outcomes of the Scientific Advisory Committee on Nutrition and World Health Organization reports
In 1994, the UK Committee on Medical Aspects of Food and Nutrition Policy (COMA 1994) recommended that the average contribution of SFA to total dietary energy be reduced to no more than 10% for adults and children aged 5 years and older (also expressed as 11% of food energy). While great strides have been made in reducing intake of SFA over the years, an average intake of SFA of 12.5% of food energy in 19-64 year-olds remains slightly above current UK recommendations (PHE 2018) . In June 2014, the Food Standards Agency in Scotland [Food Standards Scotland (FSS)] requested that SACN undertake a review of the evidence on the health effects of fats, including monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA) and, in particular, SFA. Following an initial scoping exercise, it was agreed that a review of the evidence on SFA across the life stages was most pressing, due to the intense scientific and media debate regarding the relationship between SFA and CVD. At a global level, the WHO Department of Nutrition for Health and Development (NHD), through the work of the Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health, updated nutrient intake goals (including SFA) for the global population for the prevention of non-communicable diseases (NCDs). These guidelines were originally established in 1989 and then updated in 2002. The recent WHO report focused on CVDs, a leading cause of NCD mortality.
The independent reports by SACN and WHO produced comparable recommendations, as summarised in Table 1 . Both draft guidelines recommend a continuation of a threshold intake of SFA of 10% total energy, with the only slight deviation in guidance being that SACN recommends replacing SFA with unsaturated fatty acids (both MUFA and PUFA), whereas WHO recommends replacement with PUFA.
Key events in the history of the saturated fat saga; the long, the short and the tall
The role of cholesterol in the pathogenesis of cardiovascular atherosclerosis was first proposed over 100 years ago, in 1913 by a Russian medical student and experimental pathologist from Saint Petersburg called Nikolai Anitschkow (Anitschow & Chalatow 1913) . In studies that were originally designed to examine the effects of dietary protein on ageing, Anitschkow made the serendipitous discovery that a high protein diet, which also happened to be high in fat and cholesterol, produced arterial lesions analogous to those of human atherosclerosis (Steinberg 2004) . Some years later, the raised concentration of blood cholesterol that was largely responsible for these arterial lesions was linked to a specific fraction of cholesterol, 'beta' or LDL by John Gofman, an atomic physicist formerly involved in the development of the atomic bomb (Gofman & Lindgren 1950) . The first evidence that blood (LDL) cholesterol can be manipulated by altering the composition of SFA and unsaturated fatty acids in the diet emerged soon after, in a series of rigorously controlled metabolic ward studies performed on the East and West coasts of the US. These independent studies produced convincing evidence that the controlled substitution of dietary SFA with unsaturated fatty acids lowered serum cholesterol (Kinsell et al. 1952; Ahrens et al. 1954) . At around the same time, a nutritional epidemiologist, Ancel Keys, was beginning to publish evidence of significant associations between serum cholesterol and CHD mortality in populations, which he believed initially could be explained by the energy contribution from total fat intake. These associations were later confirmed to be associated with energy from SFA in Keys' epic Seven Countries Study. This was an observational cohort study, which examined the inter-relationships between lifestyle factors, health biomarkers and CHD (Keys et al. 1966) . It was initiated in 1958, with data collection and analysis spanning several decades. It was a huge undertaking which necessitated ongoing collaboration among scientists worldwide. The primary (Pett et al. 2017 ). This paper examines the primary source material and provides explanations for many of the common methodological criticisms aimed at the Seven Countries Study. It vindicates a man who has done so much to establish the dietary guideline on SFA and in doing so, prevent an immeasurable number of premature deaths from CHD. In 1983, the first official dietary guideline to reduce intake of total fat to 30%, and SFA to 10%, of total energy was published in the UK by the National Advisory Committee on Nutritional Education (NACNE) (Walker 1983 ). This was followed in 1984 by the landmark Coronary Primary Prevention Trial, the first large, randomised, double-blind primary intervention trial to show that decreasing blood cholesterol (using cholestyramine, a bile salt sequestrant) significantly reduced CHD events (Rifkind 1984) . From this point herein, reducing serum cholesterol became a major therapeutic target for public health, and the focus of subsequent government reports on diet and CVD (e.g. COMA 1994).
The short-term history of events that were to challenge the dietary guideline to limit intake of SFA, and which led to the SACN and WHO reports, began in 2010 with the publication of a systematic review and meta-analysis of prospective cohort studies that found no significant relationship between SFA and CHD mortality (Siri-Tarino et al. 2010). This was followed by a series of studies exhumed from the 1960s and 1970s, which were upheld in the media as evidence to challenge the guideline to restrict intake of SFA, and, furthermore, implicate n-6 PUFA (specifically linoleic acid) in the development of CVD. The most notable of these studies was the Sydney Diet Heart Study, an intervention trial from the 1970s that replaced SFA with PUFA, primarily in safflower oil and margarine. The reanalysis of data from this study revealed increases of 20% and 30% in CVD and CHD mortality, respectively, when SFA was replaced with n-6 PUFA (specifically linoleic acid), and non-significant decreases (20%) in these CVD and CHD endpoints with increased intake of SFA (Ramsden et al. 2013) . However, the trial was seriously confounded by the unmeasured intake of trans fatty acids from the margarine, and increase in the intake of linoleic acid (from 6.1% to 15.4%) to a level far in excess of the recommended upper limit of 10% of total dietary energy. Then came a meta-analysis of prospective cohort and randomised controlled trials that many believed would seal the fate of the dietary guideline to restrict SFA (Chowdhury et al. 2014 ). This study, based in Cambridge and partly funded by the British Heart Foundation and Medical Research Council, also found no significant association between SFA and relative risk of CHD and concluded: 'Evidence does not clearly support guidelines that encourage a high consumption of polyunsaturated fatty acids and low consumption of total saturated fats'. It was shown subsequently that replacement of SFA with PUFA in this study was associated with a 19% reduction in CHD risk, when the Sydney Diet Heart Study was removed from the analysis (Siri-Tarino et al. 2015). Moreover, there was unreported evidence in the supplementary data that higher intakes of SFA were linked to 'higher coronary outcomes', an unclassified description of cardiac events and/or mortality. The finding that the replacement of SFA might be associated with reduced cardiac events was later confirmed in a Cochrane systematic review and meta-analysis by Hooper et al. (2015) . In this review, the replacement of SFA with PUFA was associated with an overall highly significant reduction in serum LDL-cholesterol, and a 27% reduction in cardiac events, particularly when SFA intake was reduced to below 10% of total energy.
The last and most recent notable study to be hailed as producing evidence to challenge the dietary guideline on SFA, was the Prospective Urban Rural Epidemiology (PURE) study (Dehghan et al. 2017 ). In the PURE study, the highest and lowest quintiles of dietary SFA, PUFA, MUFA and carbohydrate intake in 135 335 participants from 18 countries (North and South America, Europe, Africa and Asia) were not associated with CVD, MI or CVD mortality, whereas carbohydrate intake was associated with total and non-CVD related mortality. However, only 11% of participants came from the US and Europe, a finding that was reflected in the low intakes of SFA and total fat of 8% and 23%, respectively, relative to the higher intakes of SFA found typically in the UK and US. Moreover, it could be argued that as rice was the primary source of dietary fat in some of the countries included in PURE, poverty and food access/availability could have been potential confounders for the association between carbohydrate intake and total mortality (with the converse being true for SFA).
It is important to understand how a situation can arise in which there is such polarised views on a dietary guideline, which many believe is supported by a totality of evidence that stretches back to the beginning of the last century. The social media has certainly played its part in reporting tall and oversimplified stories of what is a complex issue. In this respect, one large-scale experiment of 'tweeting' true and false stories on Twitter showed that false news travelled significantly faster, further and deeper than the truth, most likely because the false news was more novel and interesting than the truth (Vosoughi et al. 2018) . When a newspaper story contains information that is relevant to human health, the consequence can be serious, as for example, when a headline about the dangers of taking statins (Miller 2016 ) apparently resulted in thousands of readers stopping their medication and risking death from CVD. The same could apply to the headline news that has actively discouraged following a dietary guideline, though the impact of this on human health is more difficult to assess.
Complacency often breeds contempt in the form of controversy, which, in the case of SFA, provided a positive stimulus to research and discover gaps in knowledge about the relationships between dietary SFA and CVD. In the triangle of evidence (Fig. 1) , the effects of dietary SFA on serum LDL-cholesterol are complex and influenced by many potentially confounding factors that were not considered in secondary meta-analyses. This includes the phenomenon of macronutrient replacement (i.e. the variable effects of unsaturated fatty acids and carbohydrates as substitutes for SFA) and how whole foods and diets moderate the effects of SFA and its substitutes on serum LDL-cholesterol and other CVD risk factors.
How and with what should dietary saturated fatty acids be replaced? 'It's not what you do, but the way that you do it!'
Both the SACN and WHO reports examined the role of nutrient substitution with respect to CVD risk reduction, and concluded that the strength of evidence supports replacement of SFA with unsaturated fatty acids (particularly PUFA). While this finding is perhaps unremarkable, given the established doseresponse relationship between serum LDL-cholesterol and individual replacement dietary fatty acids (Micha & Mozaffarian 2010) , it is diametrically opposed to the idea that dietary PUFA (specifically linoleic acid) promotes the development of cardiovascular atherosclerosis by increasing oxidative and inflammatory stress. On the other hand, the benefits of replacing SFA with PUFA do concur with the complete lack of any credible evidence for this PUFA oxidation theory. In terms of lipid chemistry, the potential of a fatty acid to oxidise in air depends on the number of double bonds in its carbon chain. This holds true for an oil that is heated in air, giving rise to variable rancidity indices of different oils of different fatty acid composition. However, this principal does not translate to the oxidative susceptibility of fatty acids once they have been incorporated into tissues of the body, otherwise highly polyunsaturated fatty acids, such as long-chain n-3 PUFA, would promote cardiovascular atherosclerosis, instead of preventing it. The same erroneous argument can be applied to cooking with SFA-rich oils. The idea that fats/oils high in SFA are healthier to cook with because of their low rancidity index (no double bonds) is countered by their adverse effects in raising serum LDL-cholesterol (the lipoprotein that undergoes oxidation in the artery wall), which far outweighs the lack of impact of SFA on lipid oxidation during cooking.
It is noteworthy that neither of the draft reports from SACN or WHO advocated replacing SFA with carbohydrate. While this substitution will invariably result in a lowering of serum LDL-cholesterol in the short-term, its adverse effects on cardio-metabolic risk factors and bodyweight in the longer term will vary according to the quality of carbohydrate (i.e. the relative intake of free sugars, starch, types of starch and fibre). More studies are clearly required that differentiate between the effects of complex and refined carbohydrate, rather than grouping them together as a singular entity.
Although the SACN report had no specific recommendations for MUFA, due to there being insufficient evidence for the benefits of MUFA (i.e. low number of studies and events), it differed from the WHO report in recommending that SFA should be replaced with MUFA (in addition to PUFA). So what was SACN's underlying rationale for this recommendation? Interest in the potential health benefits for dietary MUFA originate from it being a principal component of the Mediterranean diet, which is the only dietary pattern shown to have efficacy in reducing CVD mortality in the renowned Prevenci on con Dieta Mediterr anea (PREDIMED) study (Estruch et al. 2013) . While dietary MUFA has been historically viewed as being neutral with respect to its effect on blood lipids, it has been shown to have a favourable effect as a substitute for SFA in lowering serum LDL-cholesterol and other CVD risk factors (Jebb et al. 2010) . It should also be appreciated that the effects of dietary MUFA may depend on the nature of its origin, with MUFA of plant and dairy origin being associated with lower CVD risk than that derived from meat, especially processed meats (De Oliveira Otto et al. 2012 ). Finally, it is possible that replacement of SFA with PUFA alone (as per WHO draft recommendations), and specifically linoleic acid, may raise intake of n-6 PUFA to above the recommended upper level of intake of 10% of total dietary energy (COMA 1994).
Nutrients do not exist in isolation but within complex packages called 'food'. When reducing intake of SFA, an increase in another nutrient is an inevitable consequence, especially when expressing SFA as % energy. The bioavailability and biological effects of SFA may also be influenced by other constituents within the food, such as minerals and fibre, often referred to as 'food matrix effects'. When a metaanalysis of The Netherlands cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC) trial agreed with the conclusions of other meta-analyses in finding no significant association between SFA and CVD, it went further to investigate the possible effects of SFA substitution, individual dietary fatty acids and food sources of these fats (Praagman et al. 2016) . This study attributed its negative findings to SFA being derived from dairy foods, such as cheese, a result that was consistent with the consensus view that SFA from fermented dairy foods is of lower CVD risk than its counterparts in other foods (Givens 2017) . While the examination of foods and individual SFAs was beyond the remit of the SACN and WHO reports, a move away from macronutrient-specific guidelines towards more foodbased recommendations seems inevitable.
Conclusion, future challenges and opportunities
The draft reports from SACN and WHO were unanimous in concluding that the guideline to restrict intake of dietary SFA to 10% total energy (approximately 20 g and 30 g per day for women and men, respectively) is still valid. A major challenge facing nutritional science now is how to achieve and sustain replacement of SFA, with consideration of the nature and dietary sources of the substitute unsaturated fatty acids. The serum LDL response to dietary SFA is also highly variable between individuals, due to innate differences in cholesterol homoeostasis. Increased understanding of the metabolic origins of this variation should make it possible to tailor dietary advice to groups of individuals who are more or less sensitive to dietary SFA, to improve health outcomes. Beyond the effect of SFA on serum cholesterol, there is emerging evidence for the benefits of replacing SFA on markers of insulin sensitivity (SACN 2018) , and other cardio-metabolic risk factors. This includes potential effects on improving vascular dysfunction, and reducing postprandial lipaemia and the deposition of ectopic fat in the liver, which, if confirmed, would confer additional health benefits upon this dietary guideline.
